Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 456.44 USD -1.91% Market Closed
Market Cap: 60.3B USD

During the last 3 months Alnylam Pharmaceuticals Inc insiders have not bought any shares, and sold 5.7m USD worth of shares. The stock price has increased by 0% over this period (open performance analysis).

The last transaction was made on Nov 17, 2025 by Fitzgerald Kevin Joseph , who sold 3.7m USD worth of ALNY shares.

Last Transactions:
Fitzgerald Kevin Joseph
$-3.7m
Greenstreet Yvonne
$-292.8k
Greenstreet Yvonne
Chief Executive Officer
$-318.6k
Garg Pushkal
$-306.9k
Garg Pushkal
Chief Business Officer
$-51.4k
Poulton Jeffrey V.
Chief Financial Officer
$-67k
Greenstreet Yvonne
Chief Executive Officer
$-156.3k
Fitzgerald Kevin Joseph
Chief Scientific Officer
$-42.9k
Tanguler Tolga
Chief Commercial Officer
$-24.6k
Reitan Colleen F
$-752.5k
Tanguler Tolga
$-86.9k
Garg Pushkal
$-125.7k
Poulton Jeffrey V.
$-28.2k
Greenstreet Yvonne
$-86.9k
Fitzgerald Kevin Joseph
$-17.5k
Bonney Michael W
$-5.1m
Tanguler Tolga
$-17.5k
Garg Pushkal
$-17.5k
Ausiello Dennis A
$-855.2k
Greenstreet Yvonne
$-5.9m
Greenstreet Yvonne
$-7.7m
Bonney Michael W
$-146.7k
Reitan Colleen F
$-8.4k
Pyott David E I
$-2.2m
Garg Pushkal
$-1.6m
Garg Pushkal
$-1.2m
Fitzgerald Kevin Joseph
$-28.9k
Garg Pushkal
$-35.2k
Greenstreet Yvonne
$-258.9k
Poulton Jeffrey V.
$-84.8k
Tanguler Tolga
$-31.8k
Fitzgerald Kevin Joseph
$-49.4k
View All Transactions

During the last 3 months Alnylam Pharmaceuticals Inc insiders have not bought any shares, and sold 5.7m USD worth of shares. The stock price has increased by 0% over this period (open performance analysis).

The last transaction was made on Nov 17, 2025 by Fitzgerald Kevin Joseph , who sold 3.7m USD worth of ALNY shares.

Sold
0-3
months
5.7m USD
6
3-6
months
6.3m USD
7
6-9
months
18.9m USD
5
9-12
months
19.5m USD
6
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD

Alnylam Pharmaceuticals Inc
Insider Trading Chart

Alnylam Pharmaceuticals Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Alnylam Pharmaceuticals Inc
Last Insider Transactions

Global
Insiders Monitor

Alnylam Pharmaceuticals Inc
Glance View

In the heart of the biotechnology revolution, Alnylam Pharmaceuticals Inc. has been a pioneering force, transforming the landscape of medicine through its innovative use of RNA interference (RNAi) technology. Founded in 2002 and based in Cambridge, Massachusetts, the company set out on a bold mission to silence disease-causing genes by targeting RNA, the intermediary that carries genetic instructions necessary for protein synthesis. This groundbreaking approach diverges from traditional methods that focus on targeting proteins directly and instead intervenes earlier in the disease process to eliminate or reduce the proteins before they can wreak havoc on the body. Fueled by extensive research and a robust pipeline, Alnylam has successfully brought several RNAi-based therapies to market, such as Onpattro and Givlaari, which address rare genetic disorders with high unmet medical needs. Alnylam's business model is centered around the commercial success of its novel therapies, partnerships with other pharmaceutical giants, and strategic collaborations for global distribution. By securing alliances with industry leaders like Sanofi and Regeneron, Alnylam has been able to expand its research capabilities and broaden its market reach. Revenue for the company is primarily driven by the sales of its approved products, which continue to grow as they gain acceptance within the medical community. Additionally, Alnylam's extensive patent portfolio and its strategic licensing agreements provide an additional revenue stream, safeguarding its innovations and ensuring it retains a competitive edge in this rapidly advancing field. Through its relentless pursuit of innovation, Alnylam continues to position itself as a trailblazer in turning the once theoretical promise of RNAi into a clinical reality.

ALNY Intrinsic Value
257.32 USD
Overvaluation 44%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top